Please login to the form below

Not currently logged in
Email:
Password:

Roche wins early US approval for skin cancer drug Erivedge

Erivedge is the first drug specifically registered to treat basal cell carcinoma

Roche and Genentech have been granted an earlier-than-expected approval in the US for Erivedge (vismodegib), the first drug specifically registered to treat basal cell carcinoma, the most common form of skin cancer.

The green light has come well ahead of the Food and Drug Administration's (FDA) March 8 deadline for reviewing the marketing application for Erivedge, which will be used in patients with locally advanced or metastatic disease who are not candidates for surgery or radiotherapy.

The new drug was fast-tracked by the FDA based on the results of the ERIVANCE BCC study, which showed that Erivedge shrank tumours or healed visible lesions in 43 per cent of patients with locally-advanced basal cell carcinoma and 30 per cent of patients with metastatic disease. The median progression-free survival for both metastatic and locally advanced patients was 9.5 months.

The approval is also a major milestone for Curis, the small biotech company which has devoted years to teasing out the metabolic pathway targeted by vismodegib.

The drug is a first-in-class oral treatment that selectively inhibits signalling in the Hedgehog pathway, which is implicated in more than 90 per cent of all basal cell cancers but found rarely in healthy tissues.

"Our understanding of molecular pathways involved in cancer, such as the Hedgehog pathway, has enabled the development of targeted drugs for specific diseases," commented Richard Pazdur, the director of the FDA's Office of Hematology and Oncology Products.

"This approach is becoming more common and will potentially allow cancer drugs to be developed more quickly," he added.

Curis will receive a $10m milestone payment following approval, having already booked $8m from Roche when the FDA accepted vismodegib's marketing application for review. The biotech firm will also receive 5-8 per cent royalties, depending on sales levels.

In the past, Roche has predicted that vismodegib could achieve sales of more than 1bn Swiss francs at peak.

31st January 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics